Contact M&A Advisor








    Highly profitable, high-growth telemedicine platform serving the German medical cannabis market

    Description

    L#20261003

    Unique opportunity to acquire a rapidly scaling, fully remote telemedicine and digital prescription, GDPR-compliant platform operating under the EU cross-border framework. The business connects over 20,000 patients with licensed doctors and pharmacies in Germany

    Licence(s) Held

    Operates under EU cross-border telemedicine framework (Physicians licensed in Germany & Poland). GDPR-compliant platform. No direct cannabis handling license required.

    Listing Details

    • Cyprus-based company operates a fully digital telemedicine platform, enabling remote consultations and digital prescriptions

    • Launched in 2024, the platform has served approximately 20,000 patients and processed over 6,500 prescriptions per month

    • Focused on deep process optimization to ensure scalability before launching targeted marketing campaigns, including Facebook advertising and affiliate marketing, and continues to implement new features to enhance user experience

    • Profitable business with margins exceeding 60%, a current revenue run rate of ~€140,000 per month, and a forecasted €1.5M by year-end, reflecting ~20% annual growth

    • Income is generated through patient appointment bookings, marketing services for pharmacies, partnerships with leading producers, and white-label product offerings.

    • Operates efficiently with ~12 staff/freelancers, leveraging front-end and back-end freelance specialists

    • Automated workflows reduce doctor consultation time by 90%, and the platform supports white-label functionality for rapid B2B expansion

    • Projected annual growth of 15–20% is driven by rising patient demand and recent liberalization of the German cannabis market

    • Seeking full sale and includes the going concern business, intellectual property, brand, patient database, and software codebase

    Basic Details

    Target Price:

    $ 0

    Gross Revenue

    $1,680,000

    EBITDA

    $1,008,000

    Business ID:

    L#20261003

    Country

    Cyprus

    Detail

    Business ID:L#20261003
    Target Price: $ 0
    Gross Revenue:$1,680,000
    EBITDA:$1,008,000
    Target Price / Revenue:TBD
    Target Price / EBITDA:TBD
    Contact M&A Advisor








      Similar Businesses

      Published on February 12, 2026 at 10:49 am. Updated on February 12, 2026 at 10:49 am


      Oilfield for sale

      PREVIOUS PROPERTY

      Subsoil Use Rights for Aktobe Oilfield Redevelopment (1.5M Tons B+C1)

      NEXT PROPERTY

      Profitable, veteran-focused virtual medical cannabis clinic in Canada

      Unique opportunity to acquire a rapidly scaling, fully remote telemedicine and digital prescription, GDPR-compliant platform operating under the EU cross-border framework. The business connects over 20,000 patients with licensed doctors and pharmacies in Germany

      Licence(s) Held

      Operates under EU cross-border telemedicine framework (Physicians licensed in Germany & Poland). GDPR-compliant platform. No direct cannabis handling license required.

      Listing Details

      • Cyprus-based company operates a fully digital telemedicine platform, enabling remote consultations and digital prescriptions

      • Launched in 2024, the platform has served approximately 20,000 patients and processed over 6,500 prescriptions per month

      • Focused on deep process optimization to ensure scalability before launching targeted marketing campaigns, including Facebook advertising and affiliate marketing, and continues to implement new features to enhance user experience

      • Profitable business with margins exceeding 60%, a current revenue run rate of ~€140,000 per month, and a forecasted €1.5M by year-end, reflecting ~20% annual growth

      • Income is generated through patient appointment bookings, marketing services for pharmacies, partnerships with leading producers, and white-label product offerings.

      • Operates efficiently with ~12 staff/freelancers, leveraging front-end and back-end freelance specialists

      • Automated workflows reduce doctor consultation time by 90%, and the platform supports white-label functionality for rapid B2B expansion

      • Projected annual growth of 15–20% is driven by rising patient demand and recent liberalization of the German cannabis market

      • Seeking full sale and includes the going concern business, intellectual property, brand, patient database, and software codebase

      MergersCorp M&A
      International As Seen On

      • brand 1
      • brand 1
      • brand 1
      • brand 1
      • brand 1